Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Abstract
All melatonin studies
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchMelatoninMelatonin (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  

A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial

Rodríguez-Rubio et al., Trials, doi:10.1186/s13063-020-04632-4, MELCOVID, NCT04568863
Aug 2020  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
18 patient melatonin late treatment RCT with results not reported over 2.5 years after completion.
3 melatonin RCTs have results missing long after expected Boukef, Piovezan, Rodríguez-Rubio
The trials report a total of 268 patients, with 2 trials having actual enrollment of 168, and the other estimated.
Rodríguez-Rubio et al., 5 Aug 2020, Double Blind Randomized Controlled Trial, placebo-controlled, Spain, trial NCT04568863 (history) (MELCOVID).
Contact: gescames@ugr.es (corresponding author), pedro.oliva@salud.madrid.org.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMelatoninAll
A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial
Miguel Rodríguez-Rubio, Juan Carlos Figueira, Darío Acuña-Castroviejo, Alberto M Borobia, Germaine Escames, Pedro De La Oliva
Trials, doi:10.1186/s13063-020-04632-4
Objectives: • Primary objective: to evaluate the effect of intravenous melatonin (IVM) on mortality in adult patients admitted to the intensive care unit (ICU) with COVID-19. • Secondary objectives: • To evaluate the effect of IVM on ICU length of stay. • To evaluate the effect of IVM on the length of mechanical ventilation (MV). • To evaluate if the use of IVM is associated with an increase in the number of ventilator-free days. • To evaluate if the use of IVM is associated with a reduced number of failing organs as determined by the sequential organ failure assessment (SOFA) scale. • To evaluate if the use of IVM is associated with a reduction of the frequency and severity of COVID-19-associated thromboembolic phenomena. • To evaluate if the use of IVM is associated with a decreased systemic inflammatory response assessed by plasma
Numbers to be randomized (sample size): A total of 18 patients will be randomized in this trial: 12 to the experimental arm and 6 to the control arm. Trial Status: Protocol version 2.0, June 5 th 2020. Trial status: recruitment not started. The first patient is expected to be recruited in October 2020. The last patient is anticipated to be recruited in August 2021. Trial registration: EU Clinical Trials Register. Date of trial registration: 10 July 2020. URL: https://www. clinicaltrialsregister.eu/ctr-search/trial/2020-001808-42/ES Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. Keywords: COVID-19, Randomized Controlled Trial, protocol, melatonin, treatment, intensive care, ARDS, inflammation Supplementary information Supplementary information accompanies this paper at https://doi.org/10. 1186/s13063-020-04632-4. Additional file 1. Full Study Protocol. Authors' contributions Clinical trial design: JCF, DAC, AMB, GE, PdlO. Recruitment: JCF. Writing of the manuscript: MRR, JCF, DAC, AMB, GE, PdlO. Clinical Trial Coordination: JFC, AMB, PdlO. The authors read and approved the final manuscript. Funding The start-up Pharmamel LTD financed the trial. The funding body had no role on the design of the study or the collection,..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit